Abstract
Atrial fibrillation (AF) can significantly increase morbidity and mortality. It is gaining in clinical and economic importance, being the most commonly encountered tachyarrhythmia in clinical practice. Stroke is the most serious complication. Evidence from AF antithrombotic treatment trials is reviewed, risk stratification of patients with AF is discussed, and recommendations for anticoagulation are presented.
| Original language | English |
|---|---|
| Pages (from-to) | 252-8 |
| Number of pages | 7 |
| Journal | Chest |
| Volume | 84 |
| Issue number | 991 |
| DOIs | |
| Publication status | Published - 1 May 2008 |